Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study

L. Del Pup; D. Postruznik; G. Corona

doi:10.1016/j.maturitas.2012.01.017

Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study

L. Del Pup, D. Postruznik, G. Corona

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

Vaginal promestriene was tested in gynecological cancer patients who suffered from severe vaginal dryness and dyspareunia. This form of estrogen has a low level of vaginal absorption and proved to be effective for vaginal atrophy. Method: 17 patients were treated with a 10 mg soft vaginal suppository daily for one month. Plasma levels of estrone sulfate (E1S), used as the marker of overall estrogenicity, were measured by liquid chromatography in combination with mass spectrometry. Results: Mean E1S levels changed from 533 (22-2920) to 374 (81-856) pg/ml (p = 0.39). Conclusion: In highly symptomatic gynecological cancer patients the level of circulating estrone sulfate was not significantly affected by vaginal promestriene treatment overall, but a wide range of levels was noted pre and post treatment in individual patients.

Original language	English
Pages (from-to)	93-94
Number of pages	2
Journal	Maturitas
Volume	72
Issue number	1
DOIs	https://doi.org/10.1016/j.maturitas.2012.01.017
Publication status	Published - May 2012

Keywords

Dyspareunia
Estrone sulphate
Female cancer patients
Promestriene
Vaginal dryness
Vaginal estrogens

ASJC Scopus subject areas

Obstetrics and Gynaecology
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/j.maturitas.2012.01.017

Cite this

@article{68812849ca9242699db6fd43c95e487c,

title = "Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study",

abstract = "Vaginal promestriene was tested in gynecological cancer patients who suffered from severe vaginal dryness and dyspareunia. This form of estrogen has a low level of vaginal absorption and proved to be effective for vaginal atrophy. Method: 17 patients were treated with a 10 mg soft vaginal suppository daily for one month. Plasma levels of estrone sulfate (E1S), used as the marker of overall estrogenicity, were measured by liquid chromatography in combination with mass spectrometry. Results: Mean E1S levels changed from 533 (22-2920) to 374 (81-856) pg/ml (p = 0.39). Conclusion: In highly symptomatic gynecological cancer patients the level of circulating estrone sulfate was not significantly affected by vaginal promestriene treatment overall, but a wide range of levels was noted pre and post treatment in individual patients.",

keywords = "Dyspareunia, Estrone sulphate, Female cancer patients, Promestriene, Vaginal dryness, Vaginal estrogens",

author = "{Del Pup}, L. and D. Postruznik and G. Corona",

year = "2012",

month = may,

doi = "10.1016/j.maturitas.2012.01.017",

language = "English",

volume = "72",

pages = "93--94",

journal = "Maturitas",

issn = "0378-5122",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients

T2 - A pilot study

AU - Del Pup, L.

AU - Postruznik, D.

AU - Corona, G.

PY - 2012/5

Y1 - 2012/5

N2 - Vaginal promestriene was tested in gynecological cancer patients who suffered from severe vaginal dryness and dyspareunia. This form of estrogen has a low level of vaginal absorption and proved to be effective for vaginal atrophy. Method: 17 patients were treated with a 10 mg soft vaginal suppository daily for one month. Plasma levels of estrone sulfate (E1S), used as the marker of overall estrogenicity, were measured by liquid chromatography in combination with mass spectrometry. Results: Mean E1S levels changed from 533 (22-2920) to 374 (81-856) pg/ml (p = 0.39). Conclusion: In highly symptomatic gynecological cancer patients the level of circulating estrone sulfate was not significantly affected by vaginal promestriene treatment overall, but a wide range of levels was noted pre and post treatment in individual patients.

AB - Vaginal promestriene was tested in gynecological cancer patients who suffered from severe vaginal dryness and dyspareunia. This form of estrogen has a low level of vaginal absorption and proved to be effective for vaginal atrophy. Method: 17 patients were treated with a 10 mg soft vaginal suppository daily for one month. Plasma levels of estrone sulfate (E1S), used as the marker of overall estrogenicity, were measured by liquid chromatography in combination with mass spectrometry. Results: Mean E1S levels changed from 533 (22-2920) to 374 (81-856) pg/ml (p = 0.39). Conclusion: In highly symptomatic gynecological cancer patients the level of circulating estrone sulfate was not significantly affected by vaginal promestriene treatment overall, but a wide range of levels was noted pre and post treatment in individual patients.

KW - Dyspareunia

KW - Estrone sulphate

KW - Female cancer patients

KW - Promestriene

KW - Vaginal dryness

KW - Vaginal estrogens

UR - http://www.scopus.com/inward/record.url?scp=84859532701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859532701&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2012.01.017

DO - 10.1016/j.maturitas.2012.01.017

M3 - Article

C2 - 22349253

AN - SCOPUS:84859532701

VL - 72

SP - 93

EP - 94

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 1

ER -

Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: A pilot study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this